The Cochrane Review Conclusion for Hepatitis C DAA Therapies is Wrong
Am J Gastroenterol
.
2018 Jan;113(1):2-4.
doi: 10.1038/ajg.2017.420.
Epub 2017 Nov 14.
Authors
Paul Y Kwo
1
,
Mitchell L Shiffman
2
,
David E Bernstein
3
4
Affiliations
1
Division of Gastroenterology/Hepatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California, USA.
2
Bon Secours Liver Institute of Virginia, Bon Secours Medical Group, Newport News and Richmond, Virginia, USA.
3
Division of Hepatology and Center for Liver Diseases, North Shore Long Island Jewish Health Care System, Manhasset, New York, USA.
4
Division of Hepatology and Sandra Atlas Bass Center for Liver Diseases, Northwell Health, Manhasset, New York, USA.
PMID:
29134963
DOI:
10.1038/ajg.2017.420
No abstract available
Publication types
Comment
MeSH terms
Antiviral Agents*
Hepacivirus
Hepatitis C*
Hepatitis C, Chronic*
Humans
Substances
Antiviral Agents